An interventional study of Patient nudge via text message and Patient nudge via phone call in Genetic Predisposition to Cancer, sponsored by Abramson Cancer Center at Penn Medicine. Enrolling by invitation at 1 site in United States. Open to female participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Abramson Cancer Center at Penn Medicine · Not applicable, Interventional, and Health services research
The objective of this project is to assess the implementation of evidence-based, digital tools to improve breast cancer risk assessment and related primary cancer prevention services for those at high risk for developing breast cancer.
The scientific aims of the study are:
Aim 1: To evaluate the impact of the addition of patient nudge strategies (SMS reminders v. patient phone support) to improve uptake of breast cancer risk assessment. (adoption). Clinical, social, and demographic factors associated with uptake will be a secondary outcome.
Aim 2: To estimate service delivery costs from the health system perspective by collecting data on team-member time (Implementation) Aim 3: To describe critical patient, provider, and systems facilitators and barriers for the implementation process using a multi-stakeholder, mixed-methods approach supported by the PRISM and RE-AIM conceptual frameworks (Adoption, Implementation, Maintenance).
Exploratory aim: To quantify the following clinical outcomes - incidence of high-risk of breast cancer determination, incidence of pathogenic variants identified, proportion of patients at high-risk of developing breast cancer with breast cancer screening imaging ordered within 3 months of high-risk determination, proportion of high-risk patients who complete initial breast cancer screening imaging within 6 months of order.
Abramson Cancer Center at Penn Medicine is the lead sponsor of 460 studies on the registry; 88 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 14 (42%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: Patients will be eligible if they:
Exclusion Criteria: Patients will be excluded if they:
EVA SMS reminders only
Other: Patient nudge via text message
EVA + patient phone support
Other: Patient nudge via phone call
The intervention involves patient nudge via text message
The intervention involves patient nudge via phone call from a study team member. The patient phone call nudge will consist of a study team member calling to inquire about receipt of EVA chatbot and barriers to completion.
Uptake of EVA with initial SMS contact
Uptake is the proportion of subjects who engage the EVA within the first month after contact
Time frame: 1 month
Uptake of EVA after patient nudge
Uptake will be summarized as a proportion of individuals who adopt EVA after patient nudge compared to those with no additional nudge. The effect of additional patient support is a comparison of proportions and will be summarized as an odds ratio
Time frame: 3 months
Uptake of digital counseling intervention
Proportion of participants eligible for genetic testing who proceed with the digital counseling intervention
Time frame: 4 months
Uptake of genetic testing
Proportion of participants eligible for genetic testing who complete genetic testing
Time frame: 3 months
Uptake of breast imaging
Proportion of participants deemed at elevated risk for breast cancer who complete screening breast imaging
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abramson Cancer Center at Penn Medicine →